Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Inhibrx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, JULY 16, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. ("INHIBRX" OR THE "COMPANY") (NASDAQ: INBX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL BIOLOGIC THERAPEUTIC CANDIDATES, TODAY ANNOUNCED IT ENTERED INTO THE SECOND AMENDMENT (THE "SECOND AMENDMENT") TO THE LOAN AND SECURITY AGREEMENT, AS AMENDED (THE "AMENDED LSA") WITH OXFORD FINANCE LLC ("OXFORD," TOGETHER WITH CERTAIN OF ITS AFFILIATES PARTY THERETO, THE "LENDERS"), PURSUANT TO WHICH THE LENDERS EXPANDED THE FACILITY TO AN AGGREGATE PRINCIPAL AMOUNT OF UP TO $500.0 MILLION (THE "CREDIT FACILITY"). THE SECOND AMENDMENT PROVIDES FOR AN ADDITIONAL TRANCHE, IN AN AGGREGATE PRINCIPAL AMOUNT OF UP TO $325.0 MILLION IN GROSS PROCEEDS, (I) $100.0 MILLION OF WHICH WAS FUNDED UPON EXECUTION OF THE SECOND AMENDMENT (THE "TERM C LOAN") AND (II) UP TO AN ADDITIONAL $225.0 MILLION OF WHICH MAY BE FUNDED IN INCREMENTS OF $50.0 MILLION OR MORE UPON THE COMPANY'S REQUEST AND AT THE LENDERS' SOLE DISCRETION (THE "TERM D LOAN").

INHIBRX ANNOUNCES AMENDED LOAN AGREEMENT WITH OXFORD FINANCE, EXPANDING TOTAL FACILITY TO $500.0 MILLION

NO FILING REVIEW ISSUES IDENTIFIED BY FDA WITH PDUFA GOAL DATE SET FOR APRIL 14, 2027 IF APPROVED, OZEKIBART WOULD BE THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA SAN DIEGO, JUNE 15, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL BIOLOGIC THERAPEUTIC CANDIDATES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED FOR FILING ITS BIOLOGICS LICENSE APPLICATION (BLA) SEEKING APPROVAL OF OZEKIBART (INBRX-109) FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA. THE FDA HAS NOT IDENTIFIED ANY FILING REVIEW ISSUES AT THIS TIME AND HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF APRIL 14, 2027.

INHIBRX ANNOUNCES U.S. FDA ACCEPTANCE OF BLA FOR OZEKIBART IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA

SAN DIEGO, MAY 14, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026. THE BIOPHARMACEUTICAL COMPANY HAS TWO PROGRAMS IN ONGOING CLINICAL TRIALS.

INHIBRX REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

INTERIM ANALYSES SHOW INBRX-106 +PEMBROLIZUMAB ACHIEVED A 44.0% CONFIRMED OBJECTIVE RESPONSE RATE (CORR): IN THE PRELIMINARY CONFIRMED RESPONSE-EVALUABLE POPULATION, THE INBRX-106 + PEMBROLIZUMAB COMBINATION ACHIEVED A CORR OF 44.0% VERSUS 21.4% WITH PEMBROLIZUMAB ALONE, REPRESENTING A 22.6% ABSOLUTE INCREASE IN CORR. SUPERIOR DEPTH OF RESPONSE: RESPONDING PATIENTS IN THE COMBINATION ARM DEMONSTRATED DEEPER TUMOR REDUCTIONS OVERALL, WITH THE MAJORITY ACHIEVING TARGET LESION SHRINKAGE EXCEEDING 50%; NOTABLY, THREE PATIENTS ACHIEVED A COMPLETE RADIOGRAPHIC RESPONSE.

INHIBRX REPORTS INTERIM PHASE 2 DATA FOR INBRX-106 IN FIRST-LINE HNSCC; INITIAL RESULTS DEMONSTRATE POTENTIAL COSTIMULATORY BENEFIT OVER PD-1 MONOTHERAPY

 EVENT TO BE WEBCAST LIVE ON MONDAY, MAY 11, 2026, AT 5:30 A.M. PT  SAN DIEGO, MAY 8, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPEUTICS FOR ONCOLOGY AND RARE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST PRESENTATION ON MONDAY, MAY 11, 2026 AT 5:30 A.M.

INHIBRX TO HOST WEBCAST PRESENTATION TO PROVIDE CLINICAL UPDATE ON INBRX-106 HEXAGON STUDY IN FIRST LINE HNSCC

SAN DIEGO, APRIL 21, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL BIOLOGIC THERAPEUTIC CANDIDATES, TODAY ANNOUNCED UPDATED INTERIM DATA FROM ITS PHASE 1/2 STUDY EVALUATING OZEKIBART (INBRX-109) IN COMBINATION WITH FOLFIRI IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, UNRESECTABLE COLORECTAL CANCER (CRC). AS OF APRIL 10, 2026, THE CUTOFF DATE, THE CRC COHORT CONTINUED TO DEMONSTRATE A COMPELLING SIGNAL OF ACTIVITY IN A HEAVILY PRETREATED PATIENT POPULATION.

INHIBRX PROVIDES CLINICAL UPDATE ON OZEKIBART (INBRX-109) IN LATE LINE COLORECTAL CANCER

 EVENT TO BE WEBCAST LIVE ON TUESDAY, APRIL 21, 2026, AT 1:30 P.M. PT  SAN DIEGO, APRIL 20, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPEUTICS FOR ONCOLOGY AND RARE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST PRESENTATION ON TUESDAY, APRIL 21, 2026 AT 1:30 P.M.

INHIBRX TO HOST WEBCAST PRESENTATION TO PROVIDE CLINICAL UPDATE ON OZEKIBART (INBRX-109) IN LATE LINE COLORECTAL CANCER

SAN DIEGO, MARCH 19, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2025. FOLLOWING THE COMPLETION OF THE SALE OF INBRX-101 (THE "101 TRANSACTION") BY INHIBRX, INC. (THE "FORMER PARENT") TO SANOFI S.A.

INHIBRX REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS

SAN DIEGO, MARCH 2, 2026 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY WITH A PIPELINE OF NOVEL BIOLOGIC THERAPEUTIC CANDIDATES, TODAY ANNOUNCED IT WILL BE PRESENTING AT THE FOLLOWING UPCOMING SCIENTIFIC CONFERENCE: ESMO SARCOMA AND RARE CANCERS CONGRESS MARCH 12TH- 14TH, 2026; LUGANO SWITZERLAND TITLE:PHASE 1 STUDY OF THE TETRAVALENT DEATH RECEPTOR 5 (DR5) AGONIST OZEKIBART (INBRX-109) COMBINED WITH IRINOTECAN (I) AND TEMOZOLOMIDE (T) IN ADOLESCENTS AND ADULTS WITH EWING SARCOMA ABSTRACT NUMBER: 84MO LEAD AUTHOR:RASHMI CHUGH, M.D. (PRESENTING AUTHOR: ANA SEBIO, M.D.

INHIBRX ANNOUNCES PARTICIPATION IN UPCOMING SCIENTIFIC CONFERENCE

SAN DIEGO , DEC. 16, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPEUTICS FOR ONCOLOGY TODAY ANNOUNCED AN UPDATE ON THE INBRX-106 PHASE 2/3 CLINICAL TRIAL IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) AS A FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) AND THE PHASE 1/2 TRIAL EVALUATING PATIENTS WITH CHECKPOINT INHIBITOR REFRACTORY OR RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) IN COMBINATION WITH KEYTRUDA. THE COMPANY ALSO PROVIDED A BRIEF PROGRESS UPDATE ON THE EXPANSION COHORTS INVESTIGATING OZEKIBART IN COMBINATION WITH FOLFIRI IN LATE-LINE COLORECTAL CANCER AND IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN REFRACTORY EWING SARCOMA.

Inhibrx, Inc.

INBX

Price

Financial Reports

No items found.

Press Releases

Inhibrx, Inc.

INBX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INBX